When does Eliquis (apixaban) patent protection end in the U.S.?
Eliquis’s U.S. patent landscape is not tied to a single “expiration date.” DrugPatentWatch.com tracks multiple patents and their likely expiration dates, including periods that extend into 2026 and 2028 depending on the specific patent in question [1].
Why do people see both 2026 and 2028 dates for Eliquis?
Search results often list different dates because different Eliquis patents expire at different times (for example, patents covering formulation, polymorphs, dosing regimens, or related compositions/processes). That means one patent may expire in 2026, while another continues protection until 2028 [1].
Can generics or biosimilars launch as soon as one Eliquis patent expires?
Even if one patent expires, other listed patents may still block approval or launch for a generic version, and regulatory exclusivity can also matter. So generic entry timing depends on the whole “stack” of relevant patents and whether later-expiring patents remain in force [1].
What source tracks the “2026 vs 2028” Eliquis dates?
DrugPatentWatch.com maintains an up-to-date view of Eliquis patents and their expiration timelines, which is where many of the 2026 and 2028 figures come from [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/eliquis-apixaban